organization · Reporting owner
ARCH Venture Fund VII, L.P.
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | 10% owner | December 22, 2020 | December 23, 2020 |
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | 10% owner | October 27, 2025 | October 29, 2025 |
| Twist Bioscience CorpTWST · Entity 3619 | 10% owner | November 02, 2018 | November 06, 2018 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | 10% owner | May 07, 2018 | May 07, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date December 22, 2020 · Filed December 23, 2020
Jointly reported with ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, BYBEE CLINTON, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 5,725,045 |
Last balance in matching sequence
After 2020-12-22 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-12-22 · Conversion · Acquired 5,425,045 · Balance 5,425,045 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 2 · 2020-12-22 · Purchase · Acquired 300,000 · Balance 5,725,045 F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-22 · Conversion · Disposed 2,927,386 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-22 · Conversion · Disposed 981,443 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-22 · Conversion · Disposed 669,977 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-22 · Conversion · Disposed 665,661 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Series E Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-12-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-22 · Conversion · Disposed 180,578 · Balance 0 F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date.
F2: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Neumora Therapeutics, Inc.
Report date October 27, 2025 · Filed October 29, 2025
Jointly reported with ARCH Venture Partners X, LLC, ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund XII, L.P. | 6,046,907 |
Reported balance
After 2025-10-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-10-27 · Purchase · Acquired 1,915,700 · Balance 6,046,907 F1: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund VII, L.P. | 1,387,228 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,387,228 F2: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund VIII Overage, L.P. | 2,321,566 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,321,566 F3: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X, L.P. | 12,205,379 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 12,205,379 F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy ARCH Venture Fund X Overage, L.P. | 11,886,758 |
Reported balance
Holding disclosure · report date 2025-10-27 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 11,886,758 F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F2: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F3: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
F4: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.
Twist Bioscience Corp
Report date November 02, 2018 · Filed November 06, 2018
Jointly reported with ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P., ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, BYBEE CLINTON, NELSEN ROBERT
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,182,645 |
Reported balance
After 2018-11-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-11-02 · Conversion · Acquired 1,182,645 · Balance 1,182,645 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,900,920 |
Reported balance
After 2018-11-02 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-11-02 · Conversion · Acquired 718,275 · Balance 1,900,920 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,167,696 |
Reported balance
After 2018-11-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-11-02 · Conversion · Acquired 266,776 · Balance 2,167,696 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,392,422 |
Reported balance
After 2018-11-02 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-11-02 · Conversion · Acquired 224,726 · Balance 2,392,422 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,407,422 |
Reported balance
After 2018-11-02 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2018-11-02 · Purchase · Acquired 15,000 · Balance 2,407,422 F4: Reflects shares purchased in the Issuer's initial public offering. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 894,146 |
Reported balance
After 2018-11-02 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2018-11-02 · Conversion · Acquired 894,146 · Balance 894,146 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 954,146 |
Reported balance
After 2018-11-02 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2018-11-02 · Purchase · Acquired 60,000 · Balance 954,146 F4: Reflects shares purchased in the Issuer's initial public offering. F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-11-02 · Conversion · Disposed 1,182,645 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-11-02 · Conversion · Disposed 718,275 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-11-02 · Conversion · Disposed 266,776 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-11-02 · Conversion · Disposed 224,726 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2018-11-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-11-02 · Conversion · Disposed 894,146 · Balance 0 F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6: The expiration date is not relevant to the conversion of these securities. F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis.
F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4: Reflects shares purchased in the Issuer's initial public offering.
F5: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F6: The expiration date is not relevant to the conversion of these securities.
Unity Biotechnology, Inc.
Report date May 07, 2018 · Filed May 07, 2018
Jointly reported with ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P., CRANDELL KEITH, BYBEE CLINTON
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,070,172 |
Reported balance
After 2018-05-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-05-07 · Conversion · Acquired 2,030,625 · Balance 2,070,172 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,298,604 |
Reported balance
After 2018-05-07 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-05-07 · Conversion · Acquired 4,228,432 · Balance 6,298,604 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 8,365,764 |
Reported balance
After 2018-05-07 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-05-07 · Conversion · Acquired 2,067,160 · Balance 8,365,764 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,486,745 |
Reported balance
After 2018-05-07 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-05-07 · Conversion · Acquired 1,486,745 · Balance 1,486,745 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,682,417 |
Reported balance
After 2018-05-07 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2018-05-07 · Conversion · Acquired 195,672 · Balance 1,682,417 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-07 · Conversion · Disposed 2,030,625 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-07 · Conversion · Disposed 4,228,432 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-07 · Conversion · Disposed 2,067,160 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-07 · Conversion · Disposed 1,486,745 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-05-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-07 · Conversion · Disposed 195,672 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2: The expiration date is not relevant to the conversion of these securities. F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
F2: The expiration date is not relevant to the conversion of these securities.
F3: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F5: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pulmatrix, Inc.
Report date April 03, 2018 · Filed April 12, 2018
Jointly reported with ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT
Section 16 reporting ended · disclosed 2018-04-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Syros Pharmaceuticals, Inc.
Report date July 15, 2019 · Filed July 17, 2019
Jointly reported with ARCH Venture Partners VII, L.P., ARCH Venture Partners VII, LLC, CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT
Section 16 reporting ended · disclosed 2019-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,302,051 |
Reported balance
After 2019-07-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-07-15 · Sale · Disposed 2,700 · Balance 4,302,051 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.40, inclusive. The reporting person undertakes to provide to Syros Pharmaceuticals, Inc., any security holder of' Syros Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. F4: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 4,276,572 |
Reported balance
After 2019-07-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-07-16 · Sale · Disposed 25,779 · Balance 4,276,572 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.825, inclusive. F4: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 4,242,051 |
Reported balance
After 2019-07-17 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2019-07-17 · Sale · Disposed 34,521 · Balance 4,242,051 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.5775 to $7.755, inclusive. F4: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.40, inclusive. The reporting person undertakes to provide to Syros Pharmaceuticals, Inc., any security holder of' Syros Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.825, inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.5775 to $7.755, inclusive.
F4: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F5: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 27, 2025 Filed Oct 29, 2025 23:19 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 1,915,700 | $2.61 | $4,999,977.00 |
DisclosureSEC source: 0001012975-25-000679 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 6,046,907 F1 · ownership.nature: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 00:52 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | OtherCommon Stock | 1,176,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-022480 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund VIII Overage, L.P. Disclosed balance after: 2,321,566 F1 · kind: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares. F2 · price: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. F3 · ownership.nature: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 00:52 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | OtherCommon Stock | 703,061 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-022480 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund VII, L.P. Disclosed balance after: 1,387,228 F1 · kind: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares. F1 · price: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares. F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries B Preferred Stock · Derivative | 2,124,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · derivative · entry 11 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,124,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F7 · ownership.nature: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-2 Preferred Stock · Derivative | 6,576,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · derivative · entry 10 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 0 Underlying: Common Stock · 6,576,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-2 Preferred Stock · Derivative | 6,895,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · derivative · entry 9 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 6,895,021 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-1 Preferred Stock · Derivative | 1,144,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · derivative · entry 8 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund VIII Overage, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,144,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F3 · ownership.nature: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionSeries A-1 Preferred Stock · Derivative | 684,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · derivative · entry 7 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 684,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | PurchaseCommon Stock | 1,500,000 | $17.00 | $25,500,000.00 |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · nonDerivative · entry 6 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 3,624,143 F7 · ownership.nature: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 2,124,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · nonDerivative · entry 5 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund XII, L.P. Disclosed balance after: 2,124,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F7 · ownership.nature: Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 6,576,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · nonDerivative · entry 4 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund X Overage, L.P. Disclosed balance after: 11,886,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 6,895,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · nonDerivative · entry 3 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund X, L.P. Disclosed balance after: 12,205,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X. F6 · ownership.nature: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 1,144,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · nonDerivative · entry 2 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund VIII Overage, L.P. Disclosed balance after: 1,144,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F3 · ownership.nature: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 10:15 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | ConversionCommon Stock | 684,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019273 · doc4.xml · nonDerivative · entry 1 ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ARCH Venture Fund VII, L.P. Disclosed balance after: 684,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 01:28 UTC | 908 Devices Inc. MASS · Entity 5564 | ConversionSeries E Preferred Stock · Derivative | 180,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138752 · tm2039218d7_4.xml · derivative · entry 7 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 180,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 01:28 UTC | 908 Devices Inc. MASS · Entity 5564 | ConversionSeries D Preferred Stock · Derivative | 665,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138752 · tm2039218d7_4.xml · derivative · entry 6 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 665,661 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 01:28 UTC | 908 Devices Inc. MASS · Entity 5564 | ConversionSeries C Preferred Stock · Derivative | 669,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138752 · tm2039218d7_4.xml · derivative · entry 5 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 669,977 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 01:28 UTC | 908 Devices Inc. MASS · Entity 5564 | ConversionSeries B Preferred Stock · Derivative | 981,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138752 · tm2039218d7_4.xml · derivative · entry 4 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 981,443 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 01:28 UTC | 908 Devices Inc. MASS · Entity 5564 | ConversionSeries A Preferred Stock · Derivative | 2,927,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138752 · tm2039218d7_4.xml · derivative · entry 3 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 2,927,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 01:28 UTC | 908 Devices Inc. MASS · Entity 5564 | PurchaseCommon Stock, par value $0.001 | 300,000 | $20.00 | $6,000,000.00 |
DisclosureSEC source: 0001104659-20-138752 · tm2039218d7_4.xml · nonDerivative · entry 2 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,725,045 F2 · ownership.direct: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 01:28 UTC | 908 Devices Inc. MASS · Entity 5564 | ConversionCommon Stock, par value $0.001 | 5,425,045 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-138752 · tm2039218d7_4.xml · nonDerivative · entry 1 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,425,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock (collectively, the "Preferred Shares") converted into 0.61459 shares of the Issuer's Common Stock automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering, and had no expiration date. F2 · ownership.direct: The securities are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the securities held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the securities held by ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 17, 2019 Filed Jul 17, 2019 23:26 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 34,521 | $7.70 | $265,687.42 |
DisclosureSEC source: 0001012975-19-000489 · edgar.xml · nonDerivative · entry 3 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,242,051 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.5775 to $7.755, inclusive. F4 · ownership.direct: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| July 16, 2019 Filed Jul 17, 2019 23:26 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 25,779 | $7.81 | $201,277.28 |
DisclosureSEC source: 0001012975-19-000489 · edgar.xml · nonDerivative · entry 2 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,276,572 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $7.825, inclusive. F4 · ownership.direct: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 23:26 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 2,700 | $8.27 | $22,315.77 |
DisclosureSEC source: 0001012975-19-000489 · edgar.xml · nonDerivative · entry 1 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,302,051 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.40, inclusive. The reporting person undertakes to provide to Syros Pharmaceuticals, Inc., any security holder of' Syros Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. F4 · ownership.direct: Beneficial ownership consists of 4,242,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| March 14, 2019 Filed Mar 14, 2019 22:57 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 43,000 | $8.15 | $350,441.40 |
DisclosureSEC source: 0001012975-19-000242 · edgar.xml · nonDerivative · entry 4 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,305,051 F4 · price: Reflects aggregation of stock sales within the range of $7.915 to $8.39. ARCH Fund VII can provide detailed support upon request. F5 · ownership.direct: Beneficial ownership consists of 4,305,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F6 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 22:57 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 2,820 | $8.20 | $23,122.03 |
DisclosureSEC source: 0001012975-19-000242 · edgar.xml · nonDerivative · entry 3 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,348,051 F3 · price: Reflects aggregation of stock sales within the range of $8.19 to $8.22. ARCH Fund VII can provide detailed support upon request. F5 · ownership.direct: Beneficial ownership consists of 4,305,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F6 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 22:57 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 81,591 | $7.89 | $643,442.94 |
DisclosureSEC source: 0001012975-19-000242 · edgar.xml · nonDerivative · entry 2 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,350,871 F2 · price: Reflects aggregation of stock sales within the range of $7.19 to $8.185. ARCH Fund VII can provide detailed support upon request. F5 · ownership.direct: Beneficial ownership consists of 4,305,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F6 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 22:57 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 40,092 | $7.37 | $295,373.80 |
DisclosureSEC source: 0001012975-19-000242 · edgar.xml · nonDerivative · entry 1 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,432,462 F1 · price: Reflects aggregation of stock sales within the range of $7.27 to $7.51. ARCH Venture Fund VII, L.P. ("ARCH Fund VII") can provide detailed support upon request. F5 · ownership.direct: Beneficial ownership consists of 4,305,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F6 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| March 11, 2019 Filed Mar 11, 2019 21:58 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 44,878 | $6.49 | $291,365.93 |
DisclosureSEC source: 0001012975-19-000225 · edgar.xml · nonDerivative · entry 3 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,472,554 F3 · price: Reflects aggregation of stock sales within the range of $6.23 to $6.63. ARCH Fund VII can provide detailed support upon request. F4 · ownership.direct: Beneficial ownership consists of 4,472,554 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 21:58 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 84,496 | $6.93 | $585,269.99 |
DisclosureSEC source: 0001012975-19-000225 · edgar.xml · nonDerivative · entry 2 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,517,432 F2 · price: Reflects aggregation of stock sales within the range of $6.50 to $7.17. ARCH Fund VII can provide detailed support upon request. F4 · ownership.direct: Beneficial ownership consists of 4,472,554 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 21:58 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 35,209 | $6.87 | $242,012.58 |
DisclosureSEC source: 0001012975-19-000225 · edgar.xml · nonDerivative · entry 1 ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,601,928 F1 · price: Reflects aggregation of stock sales within the range of $6.66 to $7.00. ARCH Venture Fund VII, L.P. ("ARCH Fund VII") can provide detailed support upon request. F4 · ownership.direct: Beneficial ownership consists of 4,472,554 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.direct: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries D Preferred Stock · Derivative | 894,146 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · derivative · entry 12 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 894,146 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F5 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries D Preferred Stock · Derivative | 224,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · derivative · entry 11 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 224,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries C Preferred Stock · Derivative | 266,776 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · derivative · entry 10 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 266,776 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries B Preferred Stock · Derivative | 718,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · derivative · entry 9 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 718,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionSeries A Preferred Stock · Derivative | 1,182,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · derivative · entry 8 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,182,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F6 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | PurchaseCommon Stock | 60,000 | $14.00 | $840,000.00 |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 7 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 954,146 F4 · shares: Reflects shares purchased in the Issuer's initial public offering. F5 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 894,146 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 6 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 894,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F5 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | PurchaseCommon Stock | 15,000 | $14.00 | $210,000.00 |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 5 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,407,422 F4 · shares: Reflects shares purchased in the Issuer's initial public offering. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 224,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 4 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,392,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 266,776 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 3 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,167,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 718,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 2 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,900,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 21:31 UTC | Twist Bioscience Corp TWST · Entity 3619 | ConversionCommon Stock | 1,182,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001012975-18-001198 · edgar.xml · nonDerivative · entry 1 ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,182,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock, for no additional consideration, on a 1:1 basis. F2 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: Clinton Bybee and Robert Nelsen are the managing directors of ARCH VII LLC and ARCH VIII LLC, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries C Preferred Stock · Derivative | 195,672 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 10 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 195,672 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F4 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries B Preferred Stock · Derivative | 1,486,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 9 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,486,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F4 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries B Preferred Stock · Derivative | 2,067,160 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 8 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,067,160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries A-2 Preferred Stock · Derivative | 4,228,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 7 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,228,432 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries A-1 Preferred Stock · Derivative | 2,030,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · derivative · entry 6 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,030,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. GPLP and GPLLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 195,672 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · nonDerivative · entry 5 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,682,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 1,486,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022043 · doc1.xml · nonDerivative · entry 4 ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,486,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F4 · ownership.nature: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F5 · ownership.nature: The managing directors of GPLLC and AVP GPLLC are Keith Crandell and Clinton Bybee, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell and Bybee disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.